These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27723777)

  • 1. Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.
    Ta MH; Schwensen KG; Foster S; Korgaonkar M; Ozimek-Kulik JE; Phillips JK; Peduto A; Rangan GK
    PLoS One; 2016; 11(10):e0164193. PubMed ID: 27723777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis.
    Oey O; Rao P; Luciuk M; Mannix C; Rogers NM; Sagar P; Wong A; Rangan G
    Exp Biol Med (Maywood); 2018 Mar; 243(5):428-436. PubMed ID: 29436846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease.
    Sagar PS; Zhang J; Luciuk M; Mannix C; Wong ATY; Rangan GK
    PLoS One; 2019; 14(1):e0209186. PubMed ID: 30601830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
    Jeewandara TM; Ameer OZ; Boyd R; Wyse BF; Underwood CF; Phillips JK
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):353-60. PubMed ID: 25676668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease.
    Ding A; Kalaignanasundaram P; Ricardo SD; Abdelkader A; Witting PK; Broughton BR; Kim HB; Wyse BF; Phillips JK; Evans RG
    Clin Exp Pharmacol Physiol; 2012 Nov; 39(11):917-29. PubMed ID: 23006058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease.
    Ta MH; Rao P; Korgaonkar M; Foster SF; Peduto A; Harris DC; Rangan GK
    Physiol Rep; 2014 Dec; 2(12):. PubMed ID: 25501440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.
    Wu M; Gu J; Mei S; Xu D; Jing Y; Yao Q; Chen M; Yang M; Chen S; Yang B; Qi N; Hu H; Wüthrich RP; Mei C
    Nephrol Dial Transplant; 2016 Nov; 31(11):1826-1834. PubMed ID: 27190325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prenatal and postnatal maternal environment on nephron endowment, renal function and blood pressure in the Lewis polycystic kidney rat.
    Ding A; Walton SL; Moritz KM; Phillips JK
    J Dev Orig Health Dis; 2019 Apr; 10(2):154-163. PubMed ID: 30274564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive renal Rel/nuclear factor-κB expression in Lewis polycystic kidney disease rats.
    Ta MH; Schwensen KG; Liuwantara D; Huso DL; Watnick T; Rangan GK
    World J Nephrol; 2016 Jul; 5(4):339-57. PubMed ID: 27458563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease.
    Phillips JK; Hopwood D; Loxley RA; Ghatora K; Coombes JD; Tan YS; Harrison JL; McKitrick DJ; Holobotvskyy V; Arnolda LF; Rangan GK
    Kidney Blood Press Res; 2007; 30(3):129-44. PubMed ID: 17446713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic effects of dietary vitamin D deficiency without increased calcium supplementation on the progression of experimental polycystic kidney disease.
    Rangan GK; Schwensen KG; Foster SL; Korgaonkar MS; Peduto A; Harris DC
    Am J Physiol Renal Physiol; 2013 Aug; 305(4):F574-82. PubMed ID: 23698116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling.
    Hakim S; Dyson JM; Feeney SJ; Davies EM; Sriratana A; Koenig MN; Plotnikova OV; Smyth IM; Ricardo SD; Hobbs RM; Mitchell CA
    Hum Mol Genet; 2016 Jun; 25(11):2295-2313. PubMed ID: 27056978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
    Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
    Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of anemia and its relationship with renal function, blood pressure, and erythropoietin in rats with chronic kidney disease.
    Phillips JK; Boyd R; Krockenberger MB; Burgio G
    Vet Clin Pathol; 2015 Sep; 44(3):342-54. PubMed ID: 26292198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of renal tissue hypoxia in a rat model of polycystic kidney disease.
    Ow CP; Abdelkader A; Hilliard LM; Phillips JK; Evans RG
    Am J Physiol Regul Integr Comp Physiol; 2014 Nov; 307(10):R1207-15. PubMed ID: 25209412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.